Gambaran Umum
Curis, Inc. is a biotechnology company based in the United States, with a primary focus on developing innovative therapeutics for the treatment of cancer. The company is actively engaged in the research and development of next-generation targeted oncology drugs that seek to modulate pathways directly involved in cancer progression and immune system regulation. Key to its portfolio is the advancement of small molecule drug candidates. Curis is notable for its collaboration with larger pharmaceutical entities, which helps accelerate the development and potential commercialization of its therapies. Among its prominent projects are inhibitors targeting the PI3K and HDAC pathways, pivotal in both tumor growth and immune response modulation. These projects underscore the company's commitment to addressing unmet medical needs in oncology through molecular insights and targeted therapy development.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Curis, Inc. per 2025 Jun 30 adalah 11.40 MM.
- Nilai operating income untuk Curis, Inc. per 2025 Jun 30 adalah -37.97 MM.
- Nilai net income untuk Curis, Inc. per 2025 Jun 30 adalah -38.92 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 11.40 | -37.97 | -38.92 |
2025-03-31 | 11.20 | -42.23 | -42.13 |
2024-12-31 | 10.91 | -44.54 | -43.39 |
2024-09-30 | 10.26 | -47.75 | -45.48 |
2024-06-30 | 10.16 | -49.55 | -47.57 |
2024-03-31 | 9.81 | -49.17 | -47.73 |
2023-12-31 | 10.02 | -48.33 | -47.41 |
2023-09-30 | 10.21 | -46.35 | -47.03 |
2023-06-30 | 10.21 | -46.59 | -48.14 |
2023-03-31 | 10.40 | -49.51 | -52.12 |
2022-12-31 | 10.16 | -53.02 | -56.67 |
2022-09-30 | 10.41 | -55.37 | -58.96 |
2022-06-30 | 10.62 | -52.81 | -56.72 |
2022-03-31 | 10.52 | -48.40 | -51.62 |
2021-12-31 | 10.65 | -42.06 | -45.44 |
2021-09-30 | 10.54 | -35.77 | -39.33 |
2021-06-30 | 10.24 | -30.43 | -34.26 |
2021-03-31 | 10.31 | -25.22 | -30.13 |
2020-12-31 | 10.84 | -24.90 | -29.91 |
2020-09-30 | 11.10 | -25.96 | -31.00 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Curis, Inc. pada 2025 Jun 30 adalah -4.48.
- laba per saham yang terdilusi untuk Curis, Inc. pada 2025 Jun 30 adalah -4.48.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -4.48 | -4.48 |
2025-03-31 | -6.03 | -6.03 |
2024-12-31 | -6.88 | |
2024-09-30 | -7.80 | -7.80 |
2024-06-30 | -8.23 | -8.23 |
2024-03-31 | -8.63 | -8.63 |
2023-12-31 | -8.96 | |
2023-09-30 | -9.30 | -9.30 |
2023-06-30 | -10.04 | -10.04 |
2023-03-31 | -11.02 | -10.93 |
2022-12-31 | -12.14 | |
2022-09-30 | -12.79 | -12.79 |
2022-06-30 | -12.38 | -12.32 |
2022-03-31 | -11.27 | -11.35 |
2021-12-31 | -9.92 | |
2021-09-30 | -9.24 | -9.24 |
2021-06-30 | -9.02 | -9.10 |
2021-03-31 | -9.57 | -9.57 |
2020-12-31 | -12.29 | |
2020-09-30 | -15.32 | -15.32 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Curis, Inc. per 2025 Jun 30 adalah -30.46 MM.
- Nilai cash from investing activities untuk Curis, Inc. per 2025 Jun 30 adalah 17.89 MM.
- Nilai kas dari aktivitas pendanaan untuk Curis, Inc. per 2025 Jun 30 adalah 12.71 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -30.46 | 17.89 | 12.71 |
2025-03-31 | -33.58 | 10.53 | 13.38 |
2024-12-31 | -39.56 | 29.44 | 3.44 |
2024-09-30 | -40.49 | 44.39 | -7.51 |
2024-06-30 | -42.73 | 26.25 | 6.57 |
2024-03-31 | -39.47 | 30.46 | 7.18 |
2023-12-31 | -38.43 | 37.79 | 7.58 |
2023-09-30 | -40.52 | 26.73 | 8.31 |
2023-06-30 | -45.46 | 30.86 | 0.42 |
2023-03-31 | -49.72 | 62.35 | 0.51 |
2022-12-31 | -54.34 | 33.02 | 0.87 |
2022-09-30 | -50.24 | 26.04 | 0.94 |
2022-06-30 | -46.73 | 10.20 | -4.67 |
2022-03-31 | -41.26 | -46.91 | -4.49 |
2021-12-31 | -37.62 | -47.90 | -4.17 |
2021-09-30 | -35.16 | -97.84 | 162.38 |
2021-06-30 | -31.43 | -86.47 | 169.16 |
2021-03-31 | -29.90 | -57.96 | 186.21 |
2020-12-31 | -25.74 | -49.05 | 188.81 |
2020-09-30 | -25.62 | 5.97 | 22.51 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | |||
2025-03-31 | |||
2024-12-31 | |||
2024-09-30 | |||
2024-06-30 | |||
2024-03-31 | |||
2023-12-31 | |||
2023-09-30 | |||
2023-06-30 | |||
2023-03-31 | |||
2022-12-31 | |||
2022-09-30 | |||
2022-06-30 | |||
2022-03-31 | |||
2021-12-31 | |||
2021-09-30 | |||
2021-06-30 | |||
2021-03-31 | |||
2020-12-31 | |||
2020-09-30 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | ||
2025-03-31 | ||
2024-12-31 | ||
2024-09-30 | ||
2024-06-30 | ||
2024-03-31 | ||
2023-12-31 | ||
2023-09-30 | ||
2023-06-30 | ||
2023-03-31 | ||
2022-12-31 | ||
2022-09-30 | ||
2022-06-30 | ||
2022-03-31 | ||
2021-12-31 | ||
2021-09-30 | ||
2021-06-30 | ||
2021-03-31 | ||
2020-12-31 | ||
2020-09-30 |
Efektivitas Manajemen
- roa untuk Curis, Inc. pada 2025 Jun 30 adalah -0.84.
- roic untuk Curis, Inc. pada 2025 Jun 30 adalah -1.16.
- croic untuk Curis, Inc. pada 2025 Jun 30 adalah -0.27.
- ocroic untuk Curis, Inc. pada 2025 Jun 30 adalah -0.93.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.84 | -1.16 | -0.27 | -0.93 | |
2025-03-31 | -0.70 | -4.45 | -1.05 | -0.09 | -0.98 |
2024-12-31 | -0.59 | -2.21 | -1.49 | -0.12 | -1.33 |
2024-09-30 | -0.53 | -1.54 | -1.15 | -0.24 | -1.04 |
2024-06-30 | -0.50 | -1.30 | -0.92 | -0.04 | -0.76 |
2024-03-31 | -0.44 | -1.02 | -2.11 | 0.31 | -1.71 |
2023-12-31 | -0.38 | -0.84 | -1.39 | -0.16 | -1.19 |
2023-09-30 | -0.37 | -0.78 | -1.63 | -0.48 | -1.54 |
2023-06-30 | -0.37 | -0.78 | -1.63 | -0.48 | -1.54 |
2023-03-31 | -0.37 | -0.69 | -1.26 | 0.32 | -1.20 |
2022-12-31 | -0.34 | -0.57 | -0.53 | -0.21 | -0.46 |
2022-09-30 | -0.34 | -0.57 | -0.53 | -0.21 | -0.46 |
2022-06-30 | -0.31 | -0.50 | -0.85 | -0.62 | -0.70 |
2022-03-31 | -0.27 | -0.42 | -0.64 | -1.15 | -0.51 |
2021-12-31 | -0.22 | -0.35 | -0.30 | -0.60 | -0.25 |
2021-09-30 | -0.86 | -0.24 | 0.18 | -0.21 | |
2021-06-30 | -0.76 | -0.29 | 0.43 | -0.26 | |
2021-03-31 | -1.13 | -0.23 | 0.76 | -0.23 | |
2020-12-31 | -0.85 | -0.22 | 0.82 | -0.19 | |
2020-09-30 | -0.73 |
Gross Margins
- marjin kotor untuk Curis, Inc. pada 2025 Jun 30 adalah -2.32.
- marjin bersih untuk Curis, Inc. pada 2025 Jun 30 adalah -3.76.
- marjin operasi untuk Curis, Inc. pada 2025 Jun 30 adalah -3.77.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | -2.32 | -3.76 | -3.77 |
2025-03-31 | 0.99 | -3.98 | -4.08 |
2024-12-31 | -2.87 | -4.43 | -4.65 |
2024-09-30 | -2.97 | -4.68 | -4.88 |
2024-06-30 | -3.10 | -4.86 | -5.01 |
2024-03-31 | -2.96 | -4.73 | -4.82 |
2023-12-31 | -2.77 | -4.60 | -4.54 |
2023-09-30 | -2.81 | -4.72 | -4.57 |
2023-06-30 | -2.81 | -4.72 | -4.57 |
2023-03-31 | -2.96 | -5.01 | -4.76 |
2022-12-31 | -3.39 | -5.66 | -5.32 |
2022-09-30 | -3.39 | -5.66 | -5.32 |
2022-06-30 | -3.10 | -5.34 | -4.97 |
2022-03-31 | -3.45 | -4.91 | -4.60 |
2021-12-31 | -2.33 | -4.27 | -3.95 |
2021-09-30 | -1.87 | -3.73 | -3.39 |
2021-06-30 | -1.57 | -3.34 | -2.97 |
2021-03-31 | -1.22 | -2.92 | -2.44 |
2020-12-31 | -1.18 | -2.76 | -2.30 |
2020-09-30 | -1.29 | -2.79 | -2.34 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1108205 |
Grupong Pang-industriya
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech) |